« Des milliers de personnes perdent la vie » sur le continent, victimes des faux médicaments, ont souligné les participants à cette conférence, à l’initiative de la fondation Chirac pour l’accès à une santé et des médicaments de qualité, la Fédération internationale des fabricants et associations pharmaceutiques (IFPMA) et l’Association pour l’information sur les médicaments (DIA).
À lire, l'article paru dans le numéro spécial de l’American Journal of Tropical Medicine and Hygiene paru en avril sur la qualité des médicaments. Selon le journal spécialisé, quelque 122 350 enfants africains sont décédés en 2013. En cause : un faux antipaludéen et un autre de piètre efficacité.
Estimated Under-Five Deaths Associated with Poor-Quality Antimalarials in Sub-Saharan Africa
+ Author Affiliations
- ↵* Address correspondence to Ramanan Laxminarayan, Center for Disease Dynamics, Economics and Policy, 1616 P Street NW, Suite 430, Washington, DC 20036. E-mail: Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.">Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.
Abstract
Many antimalarials sold in sub-Saharan Africa are poor-quality (falsified, substandard, or degraded), and the burden of disease caused by this problem is inadequately quantified. In this article, we estimate the number of under-five deaths caused by ineffective treatment of malaria, because of consumption of poor-quality antimalarials in 39 sub-Saharan countries. Our estimates were calculated as the product of the number of private sector antimalarials consumed by malaria-positive children in 2013; the proportion of private sector antimalarials consumed that were of poor-quality; and the case fatality rate (CFR) of under-five malaria-positive children who did not receive appropriate treatment in each country and involved uncertainty analysis using the Latin hypercube sampling. An estimated 122,350 (interquartile range [IQR]: 91,577–154,736) under-five malaria deaths were associated with consumption of poor-quality antimalarials, representing 3.75% (IQR: 2.81–4.75%) of all under-five deaths in our sample of 39 countries. There is considerable uncertainty surrounding our results because of gaps in data on case fatality rates and prevalence of poor-quality antimalarials. Our analysis highlights the need for further investigation into the distribution of poor-quality antimalarials and the need for stronger surveillance and regulatory efforts to prevent the sale of poor-quality antimalarials.
Footnotes
-
Financial support: This study was supported by grants from the U.S. Institute of Medicine, the Health Grand Challenges Program at Princeton University, and the Global Antibiotic Resistance Partnership. The Antimalarial Quality Surveyor of WWARN has been funded by the French Ministry of Foreign and European Affairs (FSP Mekong Project), the Bill and Melinda Gates Foundation and the Wellcome Trust of Great Britain.
- Received November 18, 2014.
- Accepted April 3, 2015.
- © The American Society of Tropical Medicine and Hygiene
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Médiapart
